Many of Australia's top brokers have been busy adjusting their financial models and recommendations again. This has led to the release of a number of broker notes this week.
Three ASX shares that brokers have named as buys this week are listed below. Here's why their analysts are feeling bullish on them right now:
Image source: Getty Images
Breville Group Ltd (ASX: BRG)
According to a note out of Morgans, its analysts have upgraded this appliance manufacturer's shares to a buy rating with a $36.05 price target. The broker highlights that Breville's shares have fallen heavily since earnings season, which it thinks has created a buying opportunity. Morgans believes Breville's premium positioning, strong focus on new product innovation, and leverage to the coffee category leave it well-placed to withstand margin pressure from tariffs and the tough consumer backdrop. Overall, the broker thinks investors should consider building a position in this high-quality, well-managed business, with structural coffee tailwinds. The Breville share price is trading at $30.81.
Life360 Inc (ASX: 360)
A note out of Bell Potter reveals that its analysts have retained their buy rating on this location technology company's shares with an improved price target of $52.50. This follows the release of Life360's quarterly update, which revealed revenue and earnings comfortably ahead of expectations. And while its monthly active users (MAU) were softer than expected, Bell Potter notes that this was due to an intentional shift in marketing to focus paid media on users who are more likely to retain and convert. In response, Bell Potter has lifted its earnings estimates through to 2028 and bumped its valuation higher. Overall, the broker thinks that weakness caused by the MAU miss has created a buying opportunity for investors. The Life360 share price is fetching $40.18 at the time of writing.
Pro Medicus Ltd (ASX: PME)
Another note out of Bell Potter reveals that its analysts have upgraded this health imaging technology company's shares to a buy rating with a $320.00 price target. The broker highlights that while it has been a quiet period with respect to new contract announcements, it is not unusual and appears confident things will pick up in due course. In the meantime, its recurring revenue will be given a boost in the near term from the implementation of contracts won in FY 2025. So, with its shares down 25% from recent highs, Bell Potter thinks that now could be a good time to hit the buy button. The Pro Medicus share price is trading at $260.49.
